Table 2

Therapeutic responses to methotrexate

ACR ≥ 20 responses at


Study/Trial

Mean disease duration

Median MTX dose (mg/week)

12 months

24 months


Haagsma, et al. [74]

3 months

10

71%

NR

Möttönen, et al. [57]

8 months

10

78%

84%

ERA [12,75]

11 months

18a

65%

59%

MN 302 [15]

3.8 years

10

65%b

72%

US 301 [5]

6.5 years

15a

46%b

67%

ASPIRE [10]

7 months

19a

54%b

NR

TEMPO [13]

6.6 years

17a

75%

71%

PREMIER [11]

8 to 9 months

16a

63%b

56%


Therapeutic responses to methotrexate (MTX) are not consistent across trials and cannot be explained solely by differences in duration of disease or median MTX dose. aWith regular folate supplementation. bDesignated 12 month outcomes were analyzed with an intention to treat (ITT) analysis with non-responder imputation (NRI) for study non-completers. All other 12 month outcomes were analyzed by ITT with last observation carried forward (LOCF) for non-completers. ACR, American College of Rheumatology; ASPIRE, Active Controlled Study of Patients Receiving Infliximab for Treatment of Rheumatoid Arthritis of Early Onset; ERA, Early Rheumatoid Arthritis; NR, not recorded; TEMPO, Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes.

Strand and Sokolove Arthritis Research & Therapy 2009 11:205   doi:10.1186/ar2555